Company news

Celldex Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

July 28, 2024

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

July 15, 2024

Celldex Therapeutics to Present at Jefferies Healthcare Conference

June 3, 2024

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

June 1, 2024

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 14, 2024

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 5, 2024

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

April 16, 2024

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 7, 2024

Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

March 4, 2024

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

March 4, 2024

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

February 28, 2024

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

February 27, 2024

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

February 25, 2024

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

February 23, 2024

Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 5, 2024

Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024

February 4, 2024

Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

November 26, 2023

Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

November 6, 2023

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

November 5, 2023

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

November 4, 2023

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 1, 2023

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023

September 25, 2023

Celldex Therapeutics to Present at Cantor Global Healthcare Conference

September 24, 2023

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 7, 2023

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

July 10, 2023

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

July 5, 2023

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

June 9, 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

June 7, 2023

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies

May 30, 2023

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™

May 14, 2023

Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 3, 2023

Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

March 28, 2023

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

February 27, 2023

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023

February 25, 2023

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

February 15, 2023

Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference

February 14, 2023

Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

February 2, 2023

BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

December 13, 2022

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

December 5, 2022

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

December 1, 2022

Celldex to Participate in Upcoming November Investor Conferences

November 9, 2022

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 8, 2022

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 7, 2022

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

July 20, 2022

Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

June 29, 2022

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

June 20, 2022

Celldex Announces Two New Appointments to its Board of Directors

June 15, 2022

Celldex to Present at the 2022 Jefferies Global Healthcare Conference

June 5, 2022

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022

May 18, 2022

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 4, 2022

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 14 decks. Every deck is listed under its year.